

Supplementary Information

CA2: We identified a female individual with ASD and a homozygous canonical splice site mutation (chr8:86377699G>A; IVS2+1G>A) in intron 2 of the *CA2* gene, encoding carbonic anhydrase II. Her parents were of Middle Eastern descent and known to be first cousins. Loss of function mutations in *CA2* cause a rare autosomal recessive syndrome of intellectual disability with osteopetrosis and renal tubular acidosis, with variable intellectual disability (Osteopetrosis, autosomal recessive 3, with renal tubular acidosis, MIM #259730). The allele in this patient is recognized as a clinically pathogenic variant¹ (ClinVar RCV000000966.2). In addition to ASD, this individual was noted to have osteopetrosis, mild corpus callosal hypogenesis, congenital hypothyroidism, and failure to thrive, which together match reported phenotypes for carbonic anhydrase II deficiency syndrome.

DDHDI: We identified a male individual with ASD with compound heterozygosity for two canonical splice site mutations (exon6:c.1311-2A>T and exon13:c.2459-2A>T in the *DDHDI* gene, encoding a brain-expressed phosphatidic acid phospholipase involved in lipid metabolism and mitochondrial function. Recessive loss-of-function mutations in *DDHDI* have been reported to cause hereditary spastic paraplegia (Spastic paraplegia 28, autosomal recessive, MIM #609340) in five pedigrees.²⁻⁴ Clinical features include progressive spastic gait with or without other neurologic complications, such as cerebellar impairment, axonal neuropathy, distal sensory loss, and/or mitochondrial impairment. To date, ASD and cognitive disturbances have not been described, although recessive loss-of-function mutations in the closely related phospholipase *DDHD2* cause spastic paraplegia, intellectual disability, short stature, and dysgenesis of the corpus callosum.⁵ The patient was originally recruited through the Autism Genetic Resource Exchange (AGRE). No additional clinical details were available.

NSUN2: A homozygous stop-gain mutation (c.C1708T;p.Q570X) in *NSUN2* was identified in a girl with ASD and ID. Her parents were of Turkish descent and were first cousins once removed. *NSUN2* encodes a 767 amino acid methyltransferase that is responsible for a critical enzymatic modification of the first position of the anticodon of tRNA-leu(CAA) to 5-methylcytosine. This modification is essential for proper anticodon pairing of tRNAs and the translation of mRNA. *NSUN2* is highly expressed during brain development, and mutations in *NSUN2* have been shown to cause autosomal recessive intellectual disability in several families (Autosomal Recessive Mental Retardation 5, MIM #611091), with autistic features reported in at least one family.⁶

PAH: We re-identified homozygous nonsense mutations in *PAH* (Phenylketonuria, MIM #261600) in two unrelated ASD individuals from consanguineous families. These findings were previously described.⁷

RARB: One male individual with ASD carried a homozygous p.C26X nonsense mutation in *RARB*. He was of Turkish descent and his parents were known to be consanguineous. *RARB* encodes a retinoic acid receptor downstream of the *FOXP2* transcription factor, and recessive LOF mutations (R119X and frameshift I403Sfs15X) and dominant *de novo* GOF mutations (R387C and R387S) have been recently described in patients with PDAC syndrome (microphthalmia, pulmonary hypoplasia, diaphragmatic hernia, and cardiac defects, Microphthalmia, syndromic 12, MIM #615524). All but one reported case ended in fetal demise, but one patient (with a *de novo* R387C mutation) survived to age 16 and suffered from intellectual disability (Srour et al, *Am J Hum Genet* 2013). The patient with a *de novo* R387 mutation lacked full features of PDAC syndrome, exhibiting microphthalmia and diaphragmatic hernia but no pulmonary or cardiac defects, raising the possibility of an expanded phenotypic spectrum. The ASD individual had, in addition to ASD, bilateral microphthalmia, and a brain MRI demonstrating hypoplastic optic nerves and optic chiasm.

RFX5: We identified a female individual with ASD who carried homozygous knockout mutations in *RFX5*, a known cause of bare lymphocyte syndrome, a recessively inherited severe primary immunodeficiency associated with failure of major histocompatibility class II gene expression⁸ (MIM #209920). The patient was of Middle Eastern ancestry and parents were second cousins. No additional clinical details regarding this ASD patient were available.

ROGDI: We found a homozygous splice-site mutation in *ROGDI* in a male individual with ASD, ID, and epilepsy. This phenotype was consistent with known recessive mutations in *ROGDI* which cause Kohlschütter-Tonz syndrome (MIM #226750), a recessively inherited brain disorder which is marked by early-onset intractable seizures, severe global developmental delay, spasticity, and amelogenesis imperfecta^{9,10}. This individual was of Turkish ancestry, and parents were first cousins.

SLCIA1: As described in the main text, we identified an autistic individual from Germany, bearing a homozygous LOF mutation in the gene *SLCIA1* (Dicarboxylic aminoaciduria, MIM #222730). This affected individual bore a homozygous c.G142T:p.E48X change that was inherited from heterozygous parents. No further clinical details were available.

USH2A: We identified a homozygous nonsense mutation in *USH2A* (Usher syndrome, type 2A, MIM #276901) in one individual. These findings were previously described¹¹ and the individual was found to suffer from hearing loss.

FEV: As described in the main text, homozygous nonsense mutations in *FEV* (p.E89X) were found in two siblings. Parents were second cousins, and mother had a history of stillbirths. The elder brother was diagnosed clinically with autism and intellectual disability (IQ 69). He suffered

from severe stereotyped, aggressive and self-injurious behaviors. He had no history of seizures. At age 10, head circumference was 55 cm (73.5%), height was 134 cm (11%), weight 46 kg (92%) with a BMI of 25.6 (99%). Exam was notable for a squarish face, high forehead, slight hypertelorism, epicanthal folds, short philtrum, broad lower lip, small teeth, prominent, low-set ears, skin hyperpigmentation, 5th finger clinodactyly of both hands, and brachydactyly of his toes. An EEG showed rolandic focus bilaterally with generalization and EKG and cardiac ultrasound were normal. The younger brother carried a clinical diagnosis of PDD-NOS and intellectual disability (IQ not measured). Head circumference at age 4 was 51 cm (29.8%), height was 101 cm (24%), weight was 18 kg (70%), and BMI was 17.7 (91%). He exhibited muscular hypotonia. Skin showed general hypopigmentation but he had two café-au-lait patches as well. No abnormal facial features were noted. An EEG was normal, as were EKG and cardiac ultrasound studies. Both brothers scored in the Autism range on ADOS testing. Vineland Adaptive Behavior Composite scores were 39 and 69, respectively.

Analysis of biallelic mutations of established medical relevance

We examined how often these biallelic missense mutations involved alleles established in ClinVar as Pathogenic or Likely Pathogenic. Of 5,852 unaffected individuals, only three harbored biallelic damaging missense mutations meeting these criteria: one unaffected individual with a homozygous p.E99Q variant in *MCCC2*, and two unaffected individuals with homozygous p.A300S mutations in *PAH*. Both *MCCC2* p.E99Q and *PAH* p.A300S are notable, despite being classified as Pathogenic, for exhibiting variable penetrance and expressivity, and both have been reported in neurotypical individuals before (**Table 3, Supplementary Table 13**). In contrast, of 2343 affected individuals, thirteen had biallelic damaging mutations with Pathogenic/Likely Pathogenic alleles in ClinVar (**Table 3, Supplementary Table 13**). All thirteen cases were diagnostic of genetic disorders with known neurodevelopmental consequences including classic metabolic diseases, mitochondrial depletion syndrome, and other syndromic conditions. These

thirteen cases, combined with the previously described eight cases involving biallelic loss of function mutations, constituted ~1% of our cohort (21 out of 2,343 affected individuals), underscoring the importance of clinical screening for monogenic recessive conditions in this patient population.


REFERENCES

- 1 Hu, P. Y. *et al.* A splice junction mutation in intron 2 of the carbonic anhydrase II gene of osteopetrosis patients from Arabic countries. *Hum Mutat* **1**, 288-292, doi:10.1002/humu.1380010404 (1992).
- 2 Tesson, C. *et al.* Alteration of fatty-acid-metabolizing enzymes affects mitochondrial form and function in hereditary spastic paraplegia. *American journal of human genetics* **91**, 1051-1064, doi:10.1016/j.ajhg.2012.11.001 (2012).
- 3 Mignarri, A. *et al.* Mitochondrial dysfunction in hereditary spastic paraparesis with mutations in DDHD1/SPG28. *J Neurol Sci* **362**, 287-291, doi:10.1016/j.jns.2016.02.007 (2016).
- 4 Miura, S. *et al.* A novel frameshift mutation of DDHD1 in a Japanese patient with autosomal recessive spastic paraplegia. *European journal of medical genetics* **59**, 413-416, doi:10.1016/j.ejmg.2016.05.010 (2016).
- 5 Gonzalez, M. *et al.* Mutations in phospholipase DDHD2 cause autosomal recessive hereditary spastic paraplegia (SPG54). *European journal of human genetics : EJHG* **21**, 1214-1218, doi:10.1038/ejhg.2013.29 (2013).
- 6 Martinez, F. J. *et al.* Whole exome sequencing identifies a splicing mutation in NSUN2 as a cause of a Dubowitz-like syndrome. *Journal of medical genetics* **49**, 380-385, doi:10.1136/jmedgenet-2011-100686 (2012).
- 7 Yu, T. W. *et al.* Using Whole-Exome Sequencing to Identify Inherited Causes of Autism. *Neuron* **77**, 259-273, doi:10.1016/j.neuron.2012.11.002 (2013).
- 8 Steimle, V. *et al.* A novel DNA-binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome). *Genes & development* **9**, 1021-1032 (1995).
- 9 Schossig, A. *et al.* Mutations in ROGDI Cause Kohlschutter-Tonz Syndrome. *American journal of human genetics* **90**, 701-707, doi:10.1016/j.ajhg.2012.02.012 (2012).
- 10 Mory, A. *et al.* A nonsense mutation in the human homolog of *Drosophila* rogdi causes Kohlschutter-Tonz syndrome. *American journal of human genetics* **90**, 708-714, doi:10.1016/j.ajhg.2012.03.005 (2012).
- 11 Lim, E. T. *et al.* Rare Complete Knockouts in Humans: Population Distribution and Significant Role in Autism Spectrum Disorders. *Neuron* **77**, 235-242, doi:10.1016/j.neuron.2012.12.029 (2013).


LIST OF SUPPLEMENTARY TABLES

- Supplementary Table 1.** ASC cohorts employed in this analysis
- Supplementary Table 2.** Rates of biallelic mutation, stratified by type of mutation
- Supplementary Table 3.** Rates of biallelic synonymous mutation, broken down per cohort
- Supplementary Table 4.** Rates of biallelic mutation, stratified by type of mutation, after normalization to biallelic synonymous variation
- Supplementary Table 5.** Rates of biallelic mutation, stratified by type of mutation, prior to normalization to biallelic synonymous variation, broken down by cohort
- Supplementary Table 6.** Rates of biallelic mutation, stratified by type of mutation, after normalization to biallelic synonymous variation, broken down by cohort
- Supplementary Table 7.** Genes with biallelic LOF mutations in ASD cases
- Supplementary Table 8.** Rates of biallelic mutation, stratified by type of mutation, maxAF, and cohort after ExAC allele filtration and normalization to biallelic synonymous variation
- Supplementary Table 9.** Genes with biallelic LOF mutations in ASD cases, after ExAC filtration
- Supplementary Table 10.** LOF alleles in ASD cases, after ExAC filtration
- Supplementary Table 11.** Genes with biallelic NsynD4 mutations only in ASD cases, after ExAC filtration
- Supplementary Table 12.** Biallelic mutations identified in cases and controls previously reported as pathogenic or likely pathogenic in ClinVar with description of disorder and mutation.
- Supplementary Table 13.** *FEV* specific RNA probes for human tissue in situ hybridization.


SUPPLEMENTARY FIGURES




Supplementary Figure 1. Analytical pipeline for potentially damaging biallelic variations in the ASC




Supplementary Figure 2. Excess of biallelic mutation in ASD overlaid with distribution of rates assessed by random sampling of cases and controls. Solid dots represent rates post-normalization for potential effects of population stratification (**Methods**) while open circles represent actual measured rates prior to normalization. Distribution of rates from 10,000 random assignments of affected status displayed as violin plots in gray. Statistical testing was performed on the post-normalization rates. **(a)** Rates of biallelic gene knockout (strict LOF) in the ASC, stratified by diagnosis and allele frequency. Rates of biallelic variation, considering **(b)** LOF variants paired with a damaging missense variant (NsynD4, predicted to be deleterious by at least 4 algorithms), **(c)** LOF or NsynD4 variants, or NsynD4 variants alone.




Supplementary Figure 3. Alleles that contribute to rare biallelic LOF events are not found in excess in the heterozygous / monoallelic state, either (a) in all samples from the ASC, or (b) when stratified by sex. This is consistent with a recessive model of disease risk (as opposed to an additive dominant/codominant model). We estimate that given our sample sizes, we are powered to detect an effect size of \sim OR 1.1 (under a dominant model) for this class of variant; e.g., these results suggest that if there is categorical risk for these variants under an additive/dominant model, the effect size is <1.1 . Error bars represent the 95% confidence intervals.




Supplementary Figure 4. Effects of sex on excess of biallelic mutation in ASD overlaid with distribution of rates assessed by random sampling of cases and controls. Solid dots represent rates post-normalization for potential effects population stratification while open circles represent actual measured rates prior to normalization. Distribution of rates from 10,000 random assignments of affected status displayed as violin plots in gray. Statistical testing was performed on the post-normalization rates. **(a)** Rates of biallelic gene knockout (strict LOF) in the ASC, stratified by diagnosis and sex. **(b, c)** Rates of biallelic variation stratified by gender, considering **(b)** LOF or damaging missense (LOF or NsynD4) variants or **(c)** damaging missense variants alone (NsynD4).




Supplementary Figure 5. Comparison of excess biallelic gene knockout (strict LOF) after filtration of commonly inactivated genes in ExAC with rates from random sampling. Solid dots represent rates post-normalization for potential effects of population stratification while open circles represent actual measured rates prior to normalization. Distribution of rates from 10,000 random assignments of affected status displayed as violin plots in gray.



Supplementary Figure 6. Reduction of background rates through filtration of homozygous alleles in ExAC **(a)** increases excess of rare biallelic damaging missense (NsynD4) mutation in sex-stratified individuals with ASD and **(b)** allows or small detectable enrichment for all missense alleles (Nsyn). Solid dots represent rates post-normalization for potential effects population stratification while open circles represent actual measured rates prior to normalization. Distribution of rates from 10,000 random assignments of affected status displayed as violin plots in gray. Statistical testing was performed on the post-normalization rates.




Supplementary Figure 7: Comparison of burdens of biallelic LOF mutations in the ASC following ExAC knockout filtering, stratified by the presence or absence of detectable *de novo* LOF mutations as reported in de Rubeis *et al*, 2014. Each comparison is against all unaffected individuals in the ASC. Error bars represent the 95% confidence intervals.




Supplementary Figure 8: Knockout of the serotonergic transcription factor *FEV/Pet-1* in two brothers with autism from the ASC. **(a)** Family pedigree and sequencing results showing two children with ASD bearing biallelic stopgain mutations in *FEV*. **(b)** The stopgain mutation in *FEV/Pet-1* lies in a highly conserved ETS DNA-binding domain. *FEV* is thought to be responsible for transcriptional regulation of serotonergic genes in the serotonergic raphe neurons, which send projections broadly throughout the human brain to regulate emotion, cognition, and motor activity. **(c-g)** *In situ* hybridization analysis demonstrates specific expression of *FEV* in developing serotonergic raphe nuclei in the developing human embryonic brain (Carnegie Stage 23). Coronal plane of section is illustrated in (c). **(d)** 252-bp sense *FEV* probe (negative control). **(e)** 252-bp antisense *FEV* probe (corresponding to NM_017521 nt. 1453-1704). Dotted boxes indicate regions presented at higher magnification in **(f)** and **(g)**, with *FEV* staining in clusters of developing serotonergic raphe nuclei (asterisks). Intense staining in the isthmus denotes expression in the developing dorsal raphe nucleus, the largest of the serotonergic nuclei. Approximate levels corresponding to midbrain, isthmus, and pons are as indicated. Abbreviations: 4v, 4th ventricle; aq, aqueduct; cb, cerebellum; ic, inferior colliculus; is, isthmus; m, medulla; mb, midbrain, p, pons; sc, superior colliculus. Scale bars: **(d,e)**, 1mm; **(f,g)**, 100 μ m.


After ExAC Allele Filtration



Supplementary Figure 9. Candidate ASD genes impacted by biallelic LOF or NsynD4 mutation identified by exclusion of genes with knockouts in ExAC or the ASC, and those with similar mutations in unaffected individuals of the ASC.



Supplementary Figure 10: Increased power to detect novel genes with at least 2 independent mutations through increased sample size. Power calculations demonstrating the ability to detect genes with biallelic events in at least 2 families assuming **a)** a 1% biallelic contribution similar to our LOF estimates and **b)** a 5% biallelic contribution similar to our missense estimates.



Supplementary Figure 11: Increased power to detect novel genes with at least 3 independent mutations through increased sample size. Power calculations demonstrating the ability to detect genes with biallelic events in at least 3 families assuming **a)** a 1% biallelic contribution similar to our LOF estimates and **b)** a 5% biallelic contribution similar to our missense estimates.

Full List of ASC Members and Affiliations

Branko Aleksic, Department of Psychiatry, Graduate School of Medicine, Nagoya University, Nagoya, Japan

Joon-Yong An, Department of Psychiatry, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California, USA,

Richard Anney, Division of Psychological Medicine & Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics & Genomics, Cardiff University, Cardiff, United Kingdom

Mykyta Artomov, Stanley Center for Psychiatric Research, Broad Institute, Cambridge, Massachusetts, USA, Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA, Harvard Medical School, Boston, Massachusetts, USA, Center for Genomic Medicine, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA,

Mafalda Barbosa, The Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA,

Catalina Betancur, Sorbonne Université, INSERM, CNRS, Neuroscience Paris Seine, Institut de Biologie Paris Seine, Paris, France

Somer Bishop, Department of Psychiatry, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California, USA,

Anders Børglum, The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Denmark, Center for Genomics and Personalized Medicine, Aarhus, Denmark, Department of Biomedicine - Human Genetics, Aarhus University, Aarhus, Denmark, Bioinformatics Research Centre, Aarhus University, Aarhus, Denmark,

Harrison Brand, Center for Genomic Medicine, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA,

Michael Breen, Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, New York, USA, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York, USA, The Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA,

Alfredo Brusco, Department of Medical Sciences, University of Torino, Turin, Italy, Medical Genetics Unit, Città della Salute e della Scienza Hospital, Turin, Italy,

Joseph Buxbaum, Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, New York, USA, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York, USA, The Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA, Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA, Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, New York, USA,

Jonas Bybjerg-Grauholm, The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Denmark, Center for Neonatal Screening, Department for Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark,

Angel Carracedo, Grupo de Medicina Xenómica, Centro de Investigación en Red de Enfermedades Raras (CIBERER), Universidade de Santiago de Compostela, Santiago de Compostela, Spain, Fundación Pública Galega de Medicina Xenómica, Servicio Galego de Saúde (SERGAS), Santiago de Compostela, Spain,

Marcus C.Y. Chan, Department of Pediatrics & Adolescent Medicine, Duchess of Kent Children's Hospital, The University of Hong Kong, Hong Kong Special Administrative Region, China,

Andreas Chiocchetti, Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Goethe University Frankfurt, Frankfurt, Germany,

Brian Chung, Department of Pediatrics & Adolescent Medicine, Duchess of Kent Children's Hospital, The University of Hong Kong, Hong Kong Special Administrative Region, China,

A. Ercument Cicek, Department of Statistics, Carnegie Mellon University, Pittsburgh, Pennsylvania, USA, Computer Engineering Department, Bilkent University, Ankara, Turkey

Ryan Collins, Center for Genomic Medicine, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA, Program in Bioinformatics and Integrative Genomics, Harvard Medical School, Boston, Massachusetts, USA,

Edwin Cook, Institute for Juvenile Research, Department of Psychiatry, University of Illinois at Chicago, Chicago, Illinois, USA,

Hilary Coon, Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA, Department of Psychiatry, University of Utah, Salt Lake City, Utah, USA,

Michael Cuccaro, John P Hussman Institute for Human Genomics, University of Miami, Miami, USA,

Aurora Curró, Medical Genetics, University of Siena, Siena, Italy,

David Cutler, Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia, USA,

Bernardo Dalla Bernardina, Child Neuropsychiatry Department, Department of Surgical Sciences, Dentistry, Gynecology and Pediatrics University of Verona, Verona, Italy, \

Mark Daly, Stanley Center for Psychiatric Research, Broad Institute, Cambridge, Massachusetts, USA, Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts,

USA, Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA, Harvard Medical School, Boston, Massachusetts, USA, Center for Genomic Medicine, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA, Institute for Molecular Medicine Finland, (FIMM), University of Helsinki, Helsinki, Finland,

Silvia De Rubeis, Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, New York, USA, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York, USA, The Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA,

Bernie Devlin, Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA, Caroline Dias, Division of Genetics, Boston Children's Hospital, Boston, Massachusetts, USA, Division of Developmental Medicine, Boston Children's Hospital, Boston, Massachusetts, USA,

Ryan Doan, Division of Genetics, Boston Children's Hospital, Boston, Massachusetts, USA, Enrico Domenici, Centre for Integrative Biology, University of Trento, Trento, Italy,

Shan Dong, Department of Psychiatry, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California, USA,

Chiara Fallerini, Medical Genetics, University of Siena, Siena, Italy,

Montserrat Fernández-Prieto, Grupo de Medicina Xenómica, Centro de Investigación en Red de Enfermedades Raras (CIBERER), Universidade de Santiago de Compostela, Santiago de Compostela, Spain, Neurogenetics Group, Instituto de Investigación Sanitaria de Santiago (IDIS-SERGAS), Santiago de Compostela, Spain,

Giovanni Battista Ferrero, Department of Public Health and Pediatrics, University of Torino, Turin, Italy, Christine Freitag, Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Goethe University Frankfurt, Frankfurt, Germany,

Menachem Fromer, Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA,

Louise Gallagher, Department of Psychiatry, School of Medicine, Trinity College Dublin, Dublin, Ireland

J. Jay Gargus, Center for Autism Research and Translation, University of California Irvine, Irvine, California, USA, Sherif Gerges, Stanley Center for Psychiatric Research, Broad Institute, Cambridge, Massachusetts, USA, Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA, Harvard Medical School, Boston, Massachusetts, USA, Center for Genomic Medicine, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA,

Daniel Geschwind, Department of Human Genetics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA, Center for Autism Research and Treatment and Program in Neurobehavioral Genetics, Semel Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA,

Michael Gill, Department of Psychiatry, School of Medicine, Trinity College Dublin, Dublin, Ireland

Elisa Giorgio, Department of Medical Sciences, University of Torino, Turin, Italy,

Javier González-Peñas, Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, IISGM, CIBERSAM, School of Medicine Complutense University, Madrid, Spain,

Jakob Grove, The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Denmark, Center for Genomics and Personalized Medicine, Aarhus, Denmark, Department of Biomedicine - Human Genetics, Aarhus University, Aarhus, Denmark,

Elizabeth Guerrero, MIND (Medical Investigation of Neurodevelopmental Disorders) Institute, University of California Davis, Davis, California, USA,

Stephen Guter, Institute for Juvenile Research, Department of Psychiatry, University of Illinois at Chicago, Chicago, Illinois, USA,

Danielle Halpern, Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, New York, USA, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York, USA,

Emily Hansen-Kiss, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA,

Xin He, Department of Human Genetics, University of Chicago, Chicago, Illinois, USA,

Gail Herman, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA,

Irva Hertz-Picciotto, MIND (Medical Investigation of Neurodevelopmental Disorders) Institute, University of California Davis, Davis, California, USA,

David Hougaard, The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Denmark, Center for Neonatal Screening, Department for Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark,

Christina Hultman, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

Iuliana Ionita-Laza, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

Suma Jacob, Institute for Juvenile Research, Department of Psychiatry, University of Illinois at Chicago, Chicago, Illinois, USA,

Jesslyn Jamison, Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, New York, USA, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York, USA,

Astanand Jugessur, Norwegian Institute of Public Health, Oslo, Norway
Miia Kaartinen, Department of Child Psychiatry, University of Tampere and Tampere University Hospital, Tampere, Finland,
Lambertus Klei, Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA,
Gun Peggy Knudsen, Norwegian Institute of Public Health, Oslo, Norway
Alexander Kolevzon, Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, New York, USA, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York, USA, Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York, USA,
Jack Kosmicki, Stanley Center for Psychiatric Research, Broad Institute, Cambridge, Massachusetts, USA, Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA, Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA, Harvard Medical School, Boston, Massachusetts, USA, Center for Genomic Medicine, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA,
Itaru Kushima, Department of Psychiatry, Graduate School of Medicine, Nagoya University, Nagoya, Japan
So Lun Lee, Department of Pediatrics & Adolescent Medicine, Duchess of Kent Children's Hospital, The University of Hong Kong, Hong Kong Special Administrative Region, China,
Terho Lehtimäki, Department of Clinical Chemistry, Fimlab Laboratories and Finnish Cardiovascular Research Center-Tampere, Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland,
Elaine Lim, Harvard Medical School, Boston, Massachusetts, USA,
Carla Lintas, Campus Bio-medico, Rome, Italy,
W. Ian Lipkin, Department of Biostatistics, Columbia University, New York, New York, USA,
Diego Lopergolo, Medical Genetics, University of Siena, Siena, Italy,
Fátima Lopes, Life and Health Sciences Research Institute, School of Medicine, University of Minho, Campus de Gualtar, Braga, Portugal,
Yunin Ludena, MIND (Medical Investigation of Neurodevelopmental Disorders) Institute, University of California Davis, Davis, California, USA,
Patricia Maciel, Life and Health Sciences Research Institute, School of Medicine, University of Minho, Campus de Gualtar, Braga, Portugal,
Per Magnus, Norwegian Institute of Public Health, Oslo, Norway,
Behrang Mahjani, Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, New York, USA, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York, USA,
Nell Maltman, Institute for Juvenile Research, Department of Psychiatry, University of Illinois at Chicago, Chicago, Illinois, USA,
Dara Manoach, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA,
Gal Meiri, Pre-School Psychiatry Unit, Soroka University Medical Center, Beer Sheva, Israel,
Idan Menashe, Pre-School Psychiatry Unit, Soroka University Medical Center, Beer Sheva, Israel,
Judith Miller, Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA, Department of Psychiatry, University of Utah, Salt Lake City, Utah, USA,
Nancy Minshew, Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA,
Eduarda Montenegro M. de Souza, Centro de Pesquisas sobre o Genoma Humano e Células tronco, Departamento de Genética e Biologia Evolutiva, Instituto de Biociências, Universidade de São Paulo, São Paulo, Brazil,
Danielle Moreira, Centro de Pesquisas sobre o Genoma Humano e Células tronco, Departamento de Genética e Biologia Evolutiva, Instituto de Biociências, Universidade de São Paulo, São Paulo, Brazil,
Eric Morrow, Department of Molecular Biology, Cell Biology and Biochemistry and Department of Psychiatry and Human Behavior, Brown University, Providence, Rhode Island, USA,
Ole Mors, The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Denmark, Psychosis Research Unit, Aarhus University Hospital, Risskov, Denmark,
Preben Bo Mortensen, The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Denmark, Center for Genomics and Personalized Medicine, Aarhus, Denmark, National Centre for Register-Based Research, Aarhus University, Aarhus, Denmark, Centre for Integrated Register-based Research, Aarhus University, Aarhus, Denmark,
Matthew Mosconi, Institute for Juvenile Research, Department of Psychiatry, University of Illinois at Chicago, Chicago, Illinois, USA,
Pierandrea Muglia, UCB Pharma, Belgium,
Maureen Mulhern, Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, New York, USA, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York, USA,

Benjamin Neale, Stanley Center for Psychiatric Research, Broad Institute, Cambridge, Massachusetts, USA, Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA, Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA,

Rachel Nguyen, Center for Autism Research and Translation, University of California Irvine, Irvine, California, USA, Merete Nordentoft, The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Denmark, Mental Health Services in the Capital Region of Denmark, Mental Health Center Copenhagen, University of Copenhagen, Copenhagen, Denmark,

Norio Ozaki, Department of Psychiatry, Graduate School of Medicine, Nagoya University, Nagoya, Japan

Aarno Palotie, Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA, Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA, Institute for Molecular Medicine Finland, (FIMM), University of Helsinki, Helsinki, Finland, Psychiatric & Neurodevelopmental Genetics Unit, Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, USA,

Mara Parellada, Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, IiSGM, CIBERSAM, School of Medicine Complutense University, Madrid, Spain,

Maria Rita Passos-Bueno, Centro de Pesquisas sobre o Genoma Humano e Células tronco, Departamento de Genética e Biologia Evolutiva, Instituto de Biociências, Universidade de São Paulo, São Paulo, Brazil,

Minshi Peng, Department of Statistics, Carnegie Mellon University, Pittsburgh, Pennsylvania, USA,

Margaret Pericak-Vance, John P Hussman Institute for Human Genomics, University of Miami, Miami, USA,

Antonio Persico, Interdepartmental Program “Autism 0-90”, Gaetano Martino University Hospital, University of Messina, Messina, Italy, Mafalda Luce Center for Pervasive Developmental Disorders, Milan, Italy,

Isaac Pessah, MIND (Medical Investigation of Neurodevelopmental Disorders) Institute, University of California Davis, Davis, California, USA,

Kaija Puura, Department of Child Psychiatry, University of Tampere and Tampere University Hospital, Tampere, Finland,

Abraham Reichenberg, Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, New York, USA, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York, USA, The Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA, Department of Environmental Medicine and Public Health, Icahn School of Medicine at Mount Sinai, New York, New York, USA,

Jennifer Reichert, Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, New York, USA, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York, USA,

Alessandra Renieri, Medical Genetics, University of Siena, Siena, Italy, Genetica Medica, Azienda Ospedaliera Universitaria Senese, Siena, Italy,

Evelise Riberi, Department of Public Health and Pediatrics, University of Torino, Turin, Italy,

Elise Robinson, Stanley Center for Psychiatric Research, Broad Institute, Cambridge, Massachusetts, USA, Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA, Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA,

Kathryn Roeder, Department of Statistics, Carnegie Mellon University, Pittsburgh, Pennsylvania, USA, Computational Biology Department, Carnegie Mellon University, Pittsburgh, Pennsylvania, USA,

Kaitlin Samocha, The Wellcome Trust Sanger Institute, Cambridge, United Kingdom,

Stephan Sanders, Department of Psychiatry, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California, USA,

Sven Sandin, Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, New York, USA, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York, USA, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

SUSA, n Santangelo, Maine Medical Center and Maine Medical Center Research Institute, Portland, Maine, USA, Department of Psychiatry, Tufts University School of Medicine, Boston, Massachusetts, USA,

F. Kyle Satterstrom, Stanley Center for Psychiatric Research, Broad Institute, Cambridge, Massachusetts, USA, Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA, Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA,

Gerry Schellenberg, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA,

Stephen Scherer, Program in Genetics and Genome Biology, The Centre for Applied Genomics, The Hospital for Sick Children, Toronto, Ontario, Canada, McLaughlin Centre, University of Toronto, Toronto, Ontario, Canada,

Sabine Schlitt, Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Goethe University Frankfurt, Frankfurt, Germany,

Rebecca Schmidt, MIND (Medical Investigation of Neurodevelopmental Disorders) Institute, University of California Davis, Davis, California, USA,

Lauren Schmitt, Institute for Juvenile Research, Department of Psychiatry, University of Illinois at Chicago, Chicago, Illinois, USA,

Grace Schwartz, Department of Psychiatry, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California, USA,

Brooke Sheppard, Department of Psychiatry, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California, USA,

Isabela Maya W. Silva, Centro de Pesquisas sobre o Genoma Humano e Células tronco, Departamento de Genética e Biologia Evolutiva, Instituto de Biociências, Universidade de São Paulo, São Paulo, Brazil,

Tarjinder Singh, Stanley Center for Psychiatric Research, Broad Institute, Cambridge, Massachusetts, USA, Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA, Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA, Harvard Medical School, Boston, Massachusetts, USA, Center for Genomic Medicine, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA,

Paige Siper, Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, New York, USA, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York, USA, The Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA,

Moyra Smith, Center for Autism Research and Translation, University of California Irvine, Irvine, California, USA,

Gabriela Soares, Center for Medical Genetics Dr Jacinto Magalhães, National Health Institute Dr. Ricardo Jorge, Porto, Portugal,

Matthew State, Department of Psychiatry, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California, USA,

Christine Stevens, Stanley Center for Psychiatric Research, Broad Institute, Cambridge, Massachusetts, USA, Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA, Harvard Medical School, Boston, Massachusetts, USA, Center for Genomic Medicine, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA,

Camilla Stoltenberg, Norwegian Institute of Public Health, Oslo, Norway

Pål Suren, Norwegian Institute of Public Health, Oslo, Norway

Ezra Susser, New York State Psychiatric Institute, New York, New York, USA, Department of Epidemiology, Mailman School of Public Health, Columbia University, Epidemiology, Mailman School of Public Health, Columbia University, New York, New York, USA,

James Sutcliffe, Vanderbilt Genetics Institute, Vanderbilt University School of Medicine, Nashville, Tennessee, USA, Department of Molecular Physiology and Biophysics and Psychiatry, Vanderbilt University School of Medicine, Nashville, Tennessee, USA,

John Sweeney, Institute for Juvenile Research, Department of Psychiatry, University of Illinois at Chicago, Chicago, Illinois, USA,

Peter Szatmari, Department of Psychiatry and Behavioural Neurosciences, Offord Centre for Child Studies, McMaster University, Hamilton, Ontario, Canada,

Michael Talkowski, Center for Genomic Medicine, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA,

Lara Tang, Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, New York, USA, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York, USA,

Flora Tassone, MIND (Medical Investigation of Neurodevelopmental Disorders) Institute, University of California Davis, Davis, California, USA, Department of Biochemistry and Molecular Medicine, University of California Davis, School of Medicine, Davis, CA, USA,

Karoline Teufel, Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Goethe University Frankfurt, Frankfurt, Germany,

Audrey Thurm, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA,

Elisabetta Trabetti, Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biology and Genetics, University of Verona, Verona, Italy,

Maria del Pilar Trelles, Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, New York, USA, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York, USA,

Christopher Walsh, Division of Genetics, Boston Children's Hospital, Boston, Massachusetts, USA,

Jiebiao Wang, Department of Statistics, Carnegie Mellon University, Pittsburgh, Pennsylvania, USA,

Lauren Weiss, Department of Psychiatry, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California, USA,

Thomas Werge, The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Denmark, Institute of Biological Psychiatry, MHC Sct. Hans, Mental Health Services Copenhagen, Roskilde, Denmark, Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark,

Donna Werling, Department of Psychiatry, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California, USA,

Emilie Wigdor, Stanley Center for Psychiatric Research, Broad Institute, Cambridge, Massachusetts, USA, Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA, Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA,

Emma Wilkinson, Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, New York, USA, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York, USA,

Jeremy Willsey, Department of Psychiatry, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California, USA,

Tim Yu, Division of Genetics, Boston Children's Hospital, Boston, Massachusetts, USA,

Mullin H.C. Yu, Department of Pediatrics & Adolescent Medicine, Duchess of Kent Children's Hospital, The University of Hong Kong, Hong Kong Special Administrative Region, China,

Ryan Yuen, Program in Genetics and Genome Biology, The Centre for Applied Genomics, The Hospital for Sick Children, Toronto, Ontario, Canada,

Elaine Zachi, Centro de Pesquisas sobre o Genoma Humano e Células tronco, Departamento de Genética e Biologia Evolutiva, Instituto de Biociências, Universidade de São Paulo, São Paulo, Brazil,

Michael Zwick, Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia, USA,